The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: corneal endothelial cell culturing. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Corneal endothelial cell culturing is a key innovation area in cell & gene therapy
Culturing corneal endothelial cells is an essential technique in regenerative medicine and ophthalmology research, as it allows for the expansion of these cells for various purposes, including corneal tissue engineering and transplantation. Corneal endothelial cells are responsible for maintaining the clarity of the cornea by regulating fluid balance. Culturing corneal endothelial cells requires adherence to strict aseptic techniques to prevent contamination. Additionally, maintaining the appropriate culture conditions, growth factors, and medium composition is essential for successful cell expansion and experimentation.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of corneal endothelial cell culturing.
Key players in corneal endothelial cell culturing – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to corneal endothelial cell culturing
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Astellas Pharma||264||Unlock Company Profile|
|Sumitomo Chemical||166||Unlock Company Profile|
|Riken||133||Unlock Company Profile|
|Lineage Cell Therapeutics||124||Unlock Company Profile|
|Senju Pharmaceutical||66||Unlock Company Profile|
|Healios||51||Unlock Company Profile|
|Novartis||38||Unlock Company Profile|
|Centre National de la Recherche Scientifique||28||Unlock Company Profile|
|Mayo Clinic||22||Unlock Company Profile|
|Ecole Normale Supérieure de Paris||21||Unlock Company Profile|
|Children's Medical Center||19||Unlock Company Profile|
|ActualEyes||19||Unlock Company Profile|
|Neurotech USA||18||Unlock Company Profile|
|Pfizer||16||Unlock Company Profile|
|Alnylam Pharmaceuticals||15||Unlock Company Profile|
|CorneaGen||13||Unlock Company Profile|
|Mitsubishi Chemical Group||13||Unlock Company Profile|
|Doshisha||13||Unlock Company Profile|
|Avita International||13||Unlock Company Profile|
|Fujifilm||13||Unlock Company Profile|
|YouHealth Eyetech||12||Unlock Company Profile|
|Acro Biomedical||11||Unlock Company Profile|
|Japan Chemical Research & Industries||10||Unlock Company Profile|
|U.S. Department of Veterans Affairs||10||Unlock Company Profile|
|Mackay Memorial Hospital||9||Unlock Company Profile|
|TreeFrog Therapeutics||9||Unlock Company Profile|
|Pandorum Technologies||8||Unlock Company Profile|
|Kala Pharmaceuticals||8||Unlock Company Profile|
|Daiichi Sankyo||7||Unlock Company Profile|
|Avellino Lab USA||7||Unlock Company Profile|
|HLB||7||Unlock Company Profile|
|International Stem Cell||7||Unlock Company Profile|
|Youvision Biotech||6||Unlock Company Profile|
|Newcells Biotech||5||Unlock Company Profile|
|BioLamina||5||Unlock Company Profile|
|Ministry of Trade and Industry, Singapore||5||Unlock Company Profile|
|Hyderabad Eye Research Foundation||5||Unlock Company Profile|
|REGENERATIVE RESEARCH FOUNDATION||4||Unlock Company Profile|
|Yang Jing||4||Unlock Company Profile|
|Massachusetts Eye and Ear Infirmary||3||Unlock Company Profile|
|Buddhist Tzu Chi Medical Foundation||3||Unlock Company Profile|
|Helio||3||Unlock Company Profile|
|Max Planck Gesellschaft zur Forderung der Wissenschaften||3||Unlock Company Profile|
|Max Planck Society||3||Unlock Company Profile|
|Nitta Gelatin||3||Unlock Company Profile|
|Artecel||2||Unlock Company Profile|
|Children's Hospital of Orange County||2||Unlock Company Profile|
|S.Biomedics||2||Unlock Company Profile|
|JCR Pharmaceuticals||2||Unlock Company Profile|
|Asan Social Welfare Foundation||2||Unlock Company Profile|
Source: GlobalData Patent Analytics
Astellas Pharma is one of the leading patent filers in corneal endothelial cell culturing. Astellas Pharma is a pharmaceutical company known for its research and development efforts in various therapeutic areas, including ophthalmology. The company investigates a variety of ocular cell types, including photoreceptor cells, corneal endothelial cells, and retinal ganglion cells. A clinically advanced program underway by the company is examining the use of retinal pigmented epithelium cells to improve vision in patients with age-related macular degeneration. Sumitomo Chemical and Riken are some of the other key patent filers in corneal endothelial cell culturing.
In terms of application diversity, Acro Biomedical leads the pack, while Daiichi Sankyo and Pandorum Technologies stood in the second and third positions, respectively. By means of geographic reach, Astellas Pharma held the top position, followed by Novartis and Sumitomo Chemical.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.